- Home
- MIY vs GALT Comparison
MIY vs GALT Comparison
Compare MIY & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIY | GALT |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.3M | 397.3M |
| IPO Year | 1994 | 2008 |
Fundamental Metrics
Financial Performance| Metric | MIY | GALT |
|---|---|---|
| Price | $11.89 | $3.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 73.6K | ★ 191.1K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.01 | $2.03 |
| 52 Week High | $12.90 | $7.13 |
Technical Indicators
Market Signals| Indicator | MIY | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 36.98 |
| Support Level | $11.87 | $2.74 |
| Resistance Level | $12.44 | $3.56 |
| Average True Range (ATR) | 0.24 | 0.23 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 100.00 | 22.09 |
Price Performance
Historical ComparisonAbout MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.